| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.pfizerltd.co.in | |
| Market Cap | 18,695.73 Cr. | |
| Enterprise Value(EV) | 16,806.07 Cr. | 2023-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 114.28 | Trailing Twelve Months Ending 2023-09 |
| Price-Earning Ratio (PE) | 35.76 | Trailing Twelve Months Ending 2023-09 |
| Industry PE | 38.37 | Trailing Twelve Months Ending 2023-09 |
| Book Value / Share | 715.44 | Trailing Twelve Months Ending 2023-09 |
| Price to Book Value | 5.71 | Calculated using Price: 4,086.70 |
| Dividend Yield | 1.71 | Period Ending 2023-03 |
| No. of Shares Subscribed | 4.57 Cr. | 45,747,732 Shares |
| FaceValue | 10 | |
| About Pfizer Ltd. | ||
| Pfizer is engaged in manufacturing, marketing, trading and export of pharmaceutical products. Pfizer scientists have produced innovative breakthroughs in a wide range of research areas, including depression, erectile dysfunction, high cholesterol, HIV infection, hypertension, bacterial infections and systemic fungal infections. The company is taking on some of the world's most difficult diseases, including cancer, arthritis, and osteoporosis. | ||
| 1 Day |
|
+0.25% |
| 1 Week |
|
-0.30% |
| 1 Month |
|
+3.60% |
| 3 Month |
|
+6.15% |
| 6 Month |
|
+2.96% |
| 1 Year |
|
-9.57% |
| 2 Year |
|
-15.85% |
| 5 Year |
|
+47.91% |
| 10 Year |
|
+227.50% |
| 9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
| Return on Equity (%) | 5.31 | 14.75 | 14.70 | 14.11 | 15.07 | 15.89 | 17.19 | 23.30 | 20.55 | |
| Return on Capital Employed (%) | 15.87 | 22.78 | 22.62 | 21.49 | 23.22 | 20.38 | 23.62 | 29.78 | 27.56 | |
| Return on Assets (%) | 4.00 | 11.22 | 10.95 | 10.36 | 11.25 | 12.20 | 13.00 | 17.24 | 16.09 |
| Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
| Shh. Funds | 1,973 | 2,164 | 2,419 | 2,683 | 3,011 | 3,395 | 2,393 | 2,864 | 3,207 | 3,273 | |
| Non Curr. Liab. | -35 | 66 | 62 | 52 | 37 | 136 | 85 | 136 | 38 | 24 | |
| Curr. Liab. | 609 | 658 | 780 | 954 | 892 | 873 | 774 | 853 | 657 | 614 | |
| Minority Int. | |||||||||||
| Equity & Liab. | 2,547 | 2,888 | 3,261 | 3,690 | 3,940 | 4,405 | 3,252 | 3,854 | 3,903 | 3,911 | |
| Non Curr. Assets | 1,295 | 1,256 | 1,210 | 1,273 | 1,225 | 1,357 | 1,344 | 1,457 | 1,378 | 1,362 | |
| Curr. Assets | 1,252 | 1,632 | 2,051 | 2,417 | 2,715 | 3,048 | 1,908 | 2,361 | 2,493 | 2,549 | |
| Misc. Exp. not W/O | |||||||||||
| Total Assets | 2,547 | 2,888 | 3,261 | 3,690 | 3,940 | 4,405 | 3,252 | 3,854 | 3,903 | 3,911 |
| Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09 Rs. Cr. TTM |
| Net Sales | 1,853 | 2,012 | 1,966 | 1,969 | 2,082 | 2,152 | 2,239 | 2,611 | 2,425 | 2,301 | |
| Other Income | 72 | 87 | 101 | 114 | 167 | 184 | 81 | 63 | 101 | 128 | |
| Total Income | 1,925 | 2,099 | 2,067 | 2,083 | 2,249 | 2,336 | 2,320 | 2,674 | 2,526 | 2,429 | |
| Total Expenditure | -1,474 | -1,579 | -1,616 | -1,468 | -1,516 | -1,579 | -1,526 | -1,775 | -1,616 | -1,622 | |
| PBIDT | 451 | 520 | 451 | 615 | 733 | 757 | 794 | 899 | 910 | 807 | |
| Interest | -2 | -1 | -2 | -1 | -2 | -11 | -15 | -11 | -13 | -12 | |
| Depreciation | -131 | -58 | -63 | -66 | -71 | -103 | -109 | -115 | -106 | -84 | |
| Taxation | -138 | -165 | -180 | -188 | -231 | -133 | -171 | -160 | -200 | -169 | |
| Exceptional Items | -111 | 10 | 130 | 33 | -20 | ||||||
| PAT | 70 | 305 | 337 | 360 | 429 | 509 | 498 | 613 | 624 | 523 | |
| Adjusted EPS | 15 | 67 | 74 | 79 | 94 | 111 | 109 | 134 | 136 | 114 |
| Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
| Cash Fr. Operatn. | 132 | 113 | 345 | 329 | 332 | 98 | 323 | 427 | 667 | 356 | |
| Cash Fr. Inv. | 103 | -89 | -701 | -250 | -238 | 35 | 1,530 | -469 | -575 | -36 | |
| Cash Fr. Finan. | -1,360 | -1 | -62 | -83 | -110 | -110 | -164 | -1,571 | -181 | -346 | |
| Net Change | -1,125 | 23 | -417 | -3 | -17 | 23 | 1,690 | -1,613 | -88 | -26 | |
| Cash & Cash Eqvt | 308 | 488 | 71 | 68 | 51 | 74 | 1,764 | 151 | 63 | 37 |
|
Fri, 08 Dec 2023
Announcement under Regulation 30 (LODR)-Newspaper Publication Pursuant to Regulation 30 read with Schedule III Part A Para A of SEBI (Listing Obligations Disclosure Requirements) Regulations 2015 we enclose herewith copies of newspaper advertisement of the Postal Ballot Notice published on December 8 2023 in Business Standard (English) and Sakaal (Marathi).Request you to take the above on record. |
|
Thu, 07 Dec 2023
Shareholder Meeting / Postal Ballot-Notice of Postal Ballot Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015 please find enclosed Notice of the Postal Ballot along with explanatory statement for seeking the approval of the Members of the Company for appointment of Mr. P. Rengan (DIN: 10362899) as a Whole-time Director of the Company designated as Executive Director - Plant Operations for a period of 5 years with effect from October 28 2023. |
|
Thu, 30 Nov 2023
Announcement under Regulation 30 (LODR)-Retirement Pursuant to Regulation 30 of the SEBI(Listing Obligations and Disclosure Requirements) Regulations 2015 the Company hereby informs that Mr. Milind Patil Chief Financial Officer of the Company has retired from the services of the Company effective close of business on November 30 2023. Consequently Mr. Patil also ceased to be a Senior Management Personnel effective the said date. |
| Mon, 11 Dec 2023 |
High Delivery Percentage
|
Higher Delivery Quantity
|
Higher Delivery Quantity and Percentage
|
Higher Trade Quantity
|
Higher Trade and Delivery Quantity
|
Equities
M.F.
Sectors
StockEdge Social